Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, South Holland, The Netherlands.
Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, South Holland, The Netherlands.
Eur J Epidemiol. 2019 Jan;34(1):67-77. doi: 10.1007/s10654-018-0444-2. Epub 2018 Sep 25.
Advanced glycation end products (AGEs) accumulate in tissues with aging and may influence age-related diseases. They can be estimated non-invasively by skin autofluorescence (SAF) using the AGE Reader™. Serum 25-hydroxyvitamin D (25(OH)D) may inhibit AGEs accumulation through anti-oxidative and anti-inflammatory properties but evidence in humans is scarce. The objective was to investigate the association between serum 25(OH)D and SAF in the population-based cohort study. Serum 25(OH)D and other covariates were measured at baseline. SAF was measured on average 11.5 years later. Known risk factors for AGE accumulation such as higher age, BMI, and coffee intake, male sex, smoking, diabetes, and decreased renal function were measured at baseline. Linear regression models were adopted to explore the association between 25(OH)D and SAF with adjustment for confounders. Interaction terms were tested to identify effect modification. The study was conducted in the general community. 2746 community-dwelling participants (age ≥ 45 years) from the Rotterdam Study were included. Serum 25(OH)D inversely associated with SAF and explained 1.5% of the variance (unstandardized B = - 0.002 (95% CI[- 0.003, - 0.002]), standardized β = - 0.125), independently of known risk factors and medication intake. The association was present in both diabetics (B = - 0.004 (95% CI[- 0.008, - 0.001]), β = - 0.192) and non-diabetics (B = - 0.002 (95% CI[- 0.003, - 0.002]), β = - 0.122), both sexes, both smokers and non-smokers and in each RS subcohort. Serum 25(OH)D concentration was significantly and inversely associated with SAF measured prospectively, also after adjustment for known risk factors for high SAF and the number of medication used, but the causal chain is yet to be explored in future studies.Clinical Trial Registry (1) Netherlands National Trial Register: Trial ID: NTR6831 ( http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=6831 ). (2) WHO International Clinical Trials Registry Platform: under shared catalogue number NTR6831 ( www.who.int/ictrp/network/primary/en/ ).
晚期糖基化终产物（AGEs）在组织中随年龄的增长而积累，可能会影响与年龄相关的疾病。可以使用AGE 阅读器™通过皮肤自发荧光（SAF）非侵入性地估计它们。血清 25-羟维生素 D（25(OH)D）可能通过抗氧化和抗炎特性抑制 AGE 积累，但人体证据有限。本研究旨在调查人群队列研究中血清 25(OH)D 与 SAF 之间的关联。在基线时测量血清 25(OH)D 和其他协变量。SAF 在平均 11.5 年后进行测量。在基线时测量已知的 AGE 积累危险因素，如年龄较高、BMI 和咖啡摄入量、男性、吸烟、糖尿病和肾功能下降。采用线性回归模型探讨 25(OH)D 与 SAF 之间的关联，并对混杂因素进行调整。测试交互项以确定效应修饰。该研究在普通社区进行。共纳入 2746 名来自鹿特丹研究的社区居民（年龄≥45 岁）。血清 25(OH)D 与 SAF 呈负相关，可解释方差的 1.5%（未标准化 B=-0.002（95%CI[-0.003，-0.002]），标准化 β=-0.125），独立于已知的危险因素和药物摄入。该关联存在于糖尿病患者（B=-0.004（95%CI[-0.008，-0.001]），β=-0.192）和非糖尿病患者（B=-0.002（95%CI[-0.003，-0.002]），β=-0.122）、男女、吸烟者和非吸烟者以及每个 RS 亚组中。血清 25(OH)D 浓度与前瞻性测量的 SAF 呈显著负相关，在调整高 SAF 的已知危险因素和使用的药物数量后也是如此，但因果关系仍有待未来研究探索。临床试验注册（1）荷兰国家试验注册处：试验 ID：NTR6831（http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=6831）。（2）世界卫生组织国际临床试验注册平台：共享目录号 NTR6831（www.who.int/ictrp/network/primary/en/）。
